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Introduction. )e role of hepatic resection in patients with liver metastases from gastroenteropancreatic neuroendocrine tumors
(GEP-NETs) is still poorly de*ned.)erefore, we examined the results obtained with surgical resection and other locoregional or
systemic therapies by reviewing the recent literature on this topic.We performed themeta-analysis for comparing surgical resection
of hepatic metastases with other treatments.Materials and Methods. In this systematic review and meta-analysis of observational
studies, the literature search was undertaken between 1990 and 2012 looking for studies evaluating the di,erent survivals between
patients treated with surgical resection of hepatic metastases and with other surgical or nonsurgical therapies. )e studies were
evaluated for quality, publication bias, and heterogeneity. Pooled hazard ratio (HR) estimates and 95% con*dence intervals (CI.95)
were calculated using *xed-e,ectsmodel.Results.We selected six studies in the review, *ve of whichwere suitable formeta-analysis.
We found a signi*cant longer survival in patients treated with hepatic resection than embolisation HR 0.34 (CI.95 0.21–0.55) or all
other nonsurgical treatments HR 0.45 (CI.95 0.34–0.60). Only one study compared surgical resection with liver transplantation and
meta-analysis was not feasible. Conclusions. Our meta-analysis provides evidence supporting the hypothesis that hepatic resection
increases overall survival in patients with livermetastases fromGEP-NETs. Further randomized clinical trials are needed to con*rm
these *ndings and it would be desirable to identify new markers to properly select patients for surgical treatment.
1. Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) are a heterogeneous group of malignancies with
various clinical presentation and growth rates [1–3]. In the
current literature, the vast majority of GEP-NETs fall into
two nearly distinct categories: pancreatic neuroendocrine
tumors, also known as islet cell tumors, and gastrointestinal
neuroendocrine tumors, usually grouped in carcinoids [4–6].
In the clinical fashion, gastrointestinal NETs tend to grow
much more slowly than pancreatic NETs and also di,er in
the tumor biology and prognosis [6–8]. It is common to *nd
these tumors in advanced stage, with metastases frequently
involving the liver [9–12]. In particular, for gastrointestinal
NETs, it is reported that nearly 50–75% of small bowel
NETs develop hepatic metastases [13–15]. Although there is
uniform consensus for the treatment of primary tumor, there
is still debate over how to manage patients with metastatic
disease. Many medical and surgical treatments have been
proposed for patients with liver metastases from NETs
[10, 16–18]. However, the exact role of liver surgery for
patients with metastatic NETs is still poorly de*ned because,
frequently, the presence of unresectable hepatic secondaries
and the inert growth, and the long-term natural history of
the disease make many problems to the evaluation of the
real e,ectiveness of hepatic surgical approach. Moreover,
a valid set of criteria for selecting patients to resection has
not been established. In the present meta-analysis, our aim
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was to examine the survival di,erences of patients treated
with surgical resection of hepatic metastases and with other
therapies.
2. Materials and Methods
2.1. Search Strategy for Review. )e literature search was
carried out, by three authors independently, by gathering
information from Medline, Embase, Ovid, Google Scholar,
and Cochrane database for studies published form January
1990 to August 2012. Search terms included “neuroendocrine
tumour” or “carcinoid tumour” or “gastrointestinal NETs”
or “liver metastases” or “hepatic metastases” or “neuroen-
docrine metastases” and “hepatectomy” or “liver resection”
or “liver transplantation.” )en, we examined all the titles
and the abstracts of the resulting articles. )e *rst step was
the selection of papers referring to the surgical treatment
of liver metastases from NETs. A.er that, we analyzed the
full articles. In addition, bibliographies and citations from
full articles and previous review publications were used to
identify other additional pertinent articles.
2.2. Inclusion and Exclusion Criteria. We considered for
inclusion all experimental and observational studies that
evaluated survival in patients a,ected by NET liver metas-
tases and treated by hepatic surgical resection or liver
transplantation or other therapies (somatostatin analogues,
hepatic embolisation/chemoembolisation, peptide receptor
therapy, chemotherapy, etc.) and submitted to watchful
waiting. All relevant studies were observational (level III
or IV of evidence, CEBM) [25] because randomized trials
comparing partial hepatectomy versus liver transplantation
or other nonsurgical therapies have never been attempted. In
this meta-analysis we considered a Cox proportional hazards
regression model or Kaplan-Meier curves to calculate the
survival di,erence among patients treated with resection of
liver metastases and other treatments. Moreover, we included
only articles written in English on human subjects with the
full text available for data retrieval. We recorded geographic
locations, time frame for NET diagnosis, and treatment in
order to avoid any possible population overlap. When two
or more studies presented possible overlap, the one of better
quality orwithmore detailed datawas included. In case of dis-
crepancies among the three reviewers they were addressed by
a joint reevaluation of the original article. Speci*c exclusion
criteria were studies considering <20 patients, or nonhuman
subjects, and non-English written articles. Furthermore, we
excluded also reviews, letters to the editor without original
data, editorials, and case reports. Conference abstracts were
also excluded due to a lack of details regarding the study
design and survival data.
2.3. Data Extraction. )ree reviewers independently extract-
ed data for selected studies using a standard data extraction
form.)ey discussed any discrepancies in appropriateness for
inclusion in the present meta-analysis and data extraction.
)e following information was then extracted from every
single study: authors, year of publication, geographical area,
population characteristics (age, sex, etc.), study design, num-
ber of patients, type of procedure applied, hazards ratios with
95% con*dence interval (CI.95), or hazards ratios extracted
from Kaplan-Meier curves. )e hazard ratio in our meta-
analysis was calculated from data obtained from published
reports, using methods previously described [26].
2.4. Quality Assessment for Included Studies. )ree authors
assessed independently the quality of each included study
by using the Newcastle-Ottawa Scale [27]. )e Newcastle-
Ottawa Scale evaluates the quality of studies analyzing three
items: selection, comparability, and outcome (cohort stud-
ies) or exposure (case-control studies). )is scale assigns a
maximum of nine points to each study: a maximum of four
points for selection, two points for comparability, and three
points for exposure/outcome. )erefore, the highest quality
is achieved by scoring nine points. In our analysis studies
of high quality were de*ned those that scored nine or eight
points and studies of medium quality those that scored seven
or six points on theNewcastle-Ottawa Scale. Any discrepancy
in quality assessment was addressed by a joint evaluation of
the original article.
2.5. Data Analysis. )e data was analyzed by R (version
2.15.0), considering signi*cant푃 < 0.05. In themeta-analysis,
a summary statistic was calculated considering the hazards
ratio for survival analysis. We used rank correlation test of
funnel plot asymmetry to test the presence of any publication
bias [28, 29]. We used I2 index and Cochran Q to assess
the heterogeneity among studies. We considered an I2 index
value > 50% a measure of heterogeneity and, for Q statistic, a푃 value < 0.10 was considered statistically signi*cant for het-
erogeneity [30]. )e *xed- and random-e,ect models were
applied to calculate the pooled estimate where appropriate.
)e primary outcome in this meta-analysis was reported as
HR (with CI.95) of overall survival in patients treated with
hepatic resections. We considered MOOSE (Meta-Analysis
Of Observational Studies in Epidemiology) guidelines for
accurately performing meta-analysis of observational studies
[31] and PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines checklist [32].
3. Results
3.1. Search Results. We identi*ed a total of 2293 articles
during the initial search (Figure 1). A.er reviewing the titles
and abstracts of these publications, 2259were found to be not
eligible as they were case reports, review articles, editorials,
nonhuman studies, or non-English articles, not focusing on
the review topic, and not meeting the inclusion criteria. In
total, 34 articles were identi*ed as potentially eligible for
this review. According to a subsequent evaluation of full-
text articles, 28 of these articles either described only the
outcome of patients treated with surgical management or
did not report any HR or Kaplan-Meier curves to compare
surgical resection of hepatic metastases with other treat-
ments (Supplemental List 1) (see Supplementary Material
available online at http://dx.doi.org/10.1155/2013/235040).We
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Table 1: Description of the included studies.
Labels Location (city, country) Publicationyear Study period
Number of patients
(liver resection/other)
5 ys OS
(liver resection/other)
Surgical resection versus other conservative treatments
Chen et al., 1998
[19] Baltimore (USA) 1998 1984–1995 15/23 73%/29%
Grazi et al., 2000
[20] Bologna (Italy) 2000 1981–1997 19/9 92.6%/18.5%
∗
Ahmed et al., 2009
[21]
Basingstoke, London,
Liverpool, Belfast, and
Southampton (UK)
2009 1973–2007 50/269 78%/52%
Surgical resection versus embolization
Yao et al., 2001 [22] Chicago (USA) 2001 1992–2000 16/20 70%/40%
Osborne et al.,
2006 [23] Tampa (USA) 2006 2000–2004
38 complete and 23
palliative/53
78% complete and 64%
palliative/35%
Surgical resection versus liver transplant
Coppa et al., 2001
[24] Milan (Italy) 2001 1987–1999 20/9 67%/70%∗Four years OS.
Studies found dur-
ing the literature search
2293
Studies considering pa-
tients treated with hepatic
resection and other treat-
ments for neuroendocrine
tumors metastasizing to liver
34
Excluded (2259)
Non-human studies, non-
English studies, not focused
on the argument, case re-
ports, review articles, edi-
torials, and series less than 20
patients
Included in the re-
view and the analysis
6
Excluded (28)
Did not fulfil primary end point
(comparison of survival of
patients treated with hepatic
resection or other treatments)
Figure 1: Flow-chart of the literature search and selection.
*nally selected six eligible articles that compared survival
between the groups using Kaplan-Meier curves (Figure 1)
[19–24]. All included studies were observational retrospective
studies. Five studies compared hepatic metastases resection
with other conservative treatments and one study compared
surgical resection with liver transplantation.
3.2. Characteristics of the Studies. )is meta-analysis includ-
ed retrospective observational studies that evaluated survival
in patients a,ected by NET comparing surgical resection
of hepatic metastases with conservative management or
other treatments (Table 1) [19–24]. Five studies compared
surgical resection with conservative treatments and one
study compared surgical resection with liver transplantation.
Among the *ve studies comparing surgical resection with
conservative treatments two studies compared surgery to
embolisation. In Table 1 we present the characteristics of
the included studies. None of the studies presented Cox
proportional hazards multivariate regression models and
HR was extracted from Kaplan-Meier curves. We could not
perform any meta-analysis about surgical resection versus
liver transplantation, because there was only one eligible
study. In this study, Coppa et al. found a non signi*cant
increased OS in the group treated with liver transplantation
versus surgical resection of liver metastases alone [24]. In
Supplemental List 1 we show also the excluded studies a.er
analyzing the full paper during the second step of our study
selection process. All these studies were observational and
retrospective andHR extraction to perform themeta-analysis
was not possible. )e majority of the excluded studies were
accurately described and summarized by a recent systematic
review by Saxena et al. [33].
3.3. Quality Assessment of the Included Studies. )e quality
of the evidence on the in7uence of surgical treatment on
survival of patients with NET liver metastases is quite low
(levels III-IV, CEBM) [25].
All studies in our meta-analysis consistently showed an
increased survival in the groups treated with surgery but
none of the studies was randomized. )e three independent
reviewers agreed that all studies were graded six or seven
points on the nine-point Newcastle-Ottawa scale for quality
(medium quality). We regarded our results to be the basis to
plan randomized clinical trials on this *eld.
3.4. Main Analysis. )e meta-analysis was performed on
*ve studies as reported in Figure 2 and considered 374
patients a,ected by NET liver metastases and treated in
a conservative manner and 161 patients treated with liver
metastases. )e heterogeneity among the studies was not
signi*cant and we used *xed-e,ect model to calculate the
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Study
Fixed e!ect model
Heterogeneity:      = 32.5%,      = 0.0865, 푄 = 7.4, df = 5, 푃 = 0.1918
Surgical resection versus conservative treatment = 1
Surgical resection versus embolization = 2
Fixed e!ect model
Fixed e!ect model
Heterogeneity:      = 0%,     = 0, 푄 = 0.9, df = 2, 푃 = 0.6465
Heterogeneity:      = 54.5%,      = 0.2533, 푄 = 4.4, df = 2, 푃 = 0.1109
Chen et al., 1998 [19]
Grazi et al., 2000 [20]
Ahmed et al., 2009 [21]
Yao et al., 2001 [22]
Osborne et al., 2006 complete [23]
Osborne et al., 2006 palliative [23]
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Figure 2: (a) Forest plot of overall survival comparison between hepatic metastasis resection versus expectant or other conserva-
tive/minimally invasive managements. (b) Analysis of OS excluding palliative surgery from data published by Osborne et al. [23].
pooled estimate. Only considering data from incomplete
cytoreduction group published by Osborne et al. we found
signi*cant heterogeneity but *xed- and random-e,ect mod-
els were similar and for this study we considered the *xed-
e,ect model [23]. We found a signi*cant increased survival
in thea group of patients treated with surgical hepatic
resections HR 0.45 (CI.95 0.34–0.60) in comparison to
conservative treatments and to embolization HR 0.34 (CI.95
0.21–0.55) (Figure 2(a)). In Figure 2(b) we reported the
same analysis excluding only the cases treated with palliative
surgery by Osborne et al. and the results were similar
[23].
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Figure 3: Funnel plot.
3.5. Risk of Bias Assessment. All the observational retrospec-
tive studies were classi*ed as medium quality. We did not
*nd any randomized clinical trial on this argument. )e
main limit to consider observational retrospective studieswas
to suppose a possible selection bias for the patients treated
with surgical resection (limited disease in comparison to the
group treated with conservative treatments). )e articles of
Yao et al. and Chen et al. stated that surgical resection and
conservative treatment groups presented comparable disease
characteristics [19, 22] and the study of Osborne et al. showed
comparable pretreatment status between surgical resection
and embolization [23]. )e article published by Ahmed et
al. presented the widest population and the patients treated
in a conservative manner were older, with low proliferative
index and high Chromogranin A [21]. )e study of Grazi
et al. did not specify the di,erences between the group
treated with surgical liver resection of NET metastases and
the conservative treatment group [20].
3.6. Publication Bias. We show in Figure 3 a funnel plot
examining possible publication bias.)ese results should be
interpreted with caution, because our meta-analysis calcu-
lation included only *ve studies (Figure 2, six dots because
one study considered separately complete and palliative
cytoreduction), and current guidelines do not recommend
testing for funnel plot asymmetry in analysis of a limited
number of studies (<10) [34]. )e study with the smallest
number of controls seems to be out of the symmetry in
the plot (Figure 3). Also the comparison between complete
cytoreductive surgery and embolization seems out of the
symmetry. Nevertheless, the rank correlation test of funnel
plot asymmetry with a 푃 value of 0.189 does not indicate
signi*cant asymmetry in the funnel plot.
4. Discussion
In patients with NETs, occurrence of hepatic secondaries is
one of the most important prognostic factors for survival
[10, 35–37]. Due to the high prevalence of distant metastases
and recurrences, NETsmust be considered to havemalignant
potential [2, 38–41]. In particular, pancreatic NETs showed
the lowest 5-year survival rates (34.1–37.6%), whereas gas-
trointestinal NETs exhibited the highest survival (85.9–88.5%
at 5 years) [2, 35, 42]. Even if these neoplasms are quite
uncommon, 2%of allmalignancies [3], the incidence ofNETs
has increased exponentially (overall 500%) over the last three
decades [3]. So the traditional assumption that these cancers
are rare is incorrect [2]. Actually, the medical and surgical
therapy of NETs is a hot topic and during the last two years
at least four reviews of the literature have been published on
this subject [6, 33, 43, 44].
)e most recent classi*cations of the 7th American Joint
Committee on Cancer/Union International Contre le Cancer
2009 (AJCC/UICC) and of the European Neuroendocrine
Tumor Society 2006 (ENETS), associated with the WHO
classi*cation 2010, segregate NETs into well-di,erentiated
neuroendocrine tumors (low and intermediate grade based
on the Ki67 labeling index, also named NET-G1 or carcinoid
and NET-G2, resp.) and into the group of neuroendocrine
carcinomas (high grade, poorly di,erentiated, also named
NEC) [40]. )ese classi*cations have provided means to
better grade and stage NETs, but although these classi*ca-
tions may be useful for primary tumors, they do not allow
the strati*cation of patients with hepatic neuroendocrine
metastases [8, 45].
Considerable controversy exists regarding the best
approach to patients with NET hepatic metastases. )e
management of these patients varies from control of
symptoms only to more aggressive surgical or conservative
therapies. For patients with unresectable liver disease,
biotherapy with somatostatin analogues, peptide-mediated
radioreceptor therapy, transarterial chemoembolisation,
selective intra-arterial radiotherapy, or new molecular
target-directed therapy can be employed [4, 44, 46], but
these therapies are considered as palliative [18]. For localized
hepatic metastases, surgical therapy appears as the most
e8cient approach [5, 16, 17, 36, 37, 47–49]. Furthermore,
surgical resection of hepatic metastases could signi*cantly
reduce carcinoid symptoms [33].
Many studies that evaluate the outcome following sur-
gical management of liver metastases from NETs have
focused solely on resection rather than combined-modality
approaches that include resection and ablation or surgery
and chemotherapy. It is well known that neuroendocrine
liver metastases recur in the most patients a.er hepatic
resection, with high recurrence rates up to 70–94% at 5 years
[8, 22, 35, 37, 49–51] and the liver is the most common
site of progression of disease (69%) [49]. )erefore, the true
curative role of liver-directed surgery was questionable and
new strategies in association to surgery should be studied. It is
important to underline that data on repeated liver surgery for
recurrent disease have been extremely limited, and the role of
repeated operations remains ill de*ned [51].
In our review and meta-analysis, we found *ve studies
comparing surgical resection of NET liver metastases with
conservative management and we observed a signi*cant
increased survival in patients treated with liver resection. It
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is important to underline that all the included studies were
observational and so the clinical evidence was low.
A recent systematic review considering 29 studies
(between 1980 and 2009) found a 5-year OS of 70.5% (range
31–100%) and a 5-year progression-free survival of 29%
(range 6–66%) [33]. Histological grade, extrahepatic disease,
and macroscopically incomplete resection of liver metastases
were associated with poor prognosis. Moreover, it was found
that the predominant histological type was carcinoid (71%)
and the most common origin was the small/large intestine
(52%) [33]. In another multi-institutional study evaluating
339 patients,Mayo et al. demonstratedwithmultivariate anal-
ysis that synchronous disease, nonfunctional NET hormonal
status, and extrahepatic disease were the most important
predictive factors of worse survival [51]. Concerning other
prognostic parameters for primary NETs and liver metas-
tases, Katz et al. demonstrated that the robust presence of
tumour-in*ltrating lymphocytes is a signi*cant predictor of
outcome [52].Moreover, it is demonstrated that Ki67 staining
of core biopsies provides an adequately reliable method of
proliferation assessment for prognosis of metastatic NETs to
the liver [45].
)e symptomatology is the most important consequence
of NETs liver metastases (particularly for carcinoid tumors).
Normally serotonin produced by a carcinoid tumor from a
primary gut localization is secreted into the portal circulation
and metabolized within the liver. )e presence of multi-
ple bilobar liver metastases will cause carcinoid syndrome
because the serotonin is notmetabolized anddirectly secreted
into the systemic circulation. Furthermore, Saxena et al.
found that 95% of patients (range 50–100%) will bene*t from
liver surgical resection by reducing symptomatology. )ey
concluded that hepatic resection was safe and e,ective in
symptomatic relief and favorable survival outcomes although
the majority of patients develop recurrence of disease. It
was hypothesized that the recognition of new markers could
better identify which patients will be selected for surgery [33].
As previously stated, we agree that data about the survival
bene*t must be interpreted with caution because they could
likely just to be the product of prudent patient selection.
Probably, in the majority of published studies, there was a
selection bias because many patients with a large number
of hepatic tumors tend to be managed without surgical
resection. Likewise, patients with synchronous disease are
more likely to be treated without surgery. As randomized
controlled trials are not available yet, the question about
the e,ectiveness of surgical resection and other treatment
modalities remains unanswered. Anyway, in our meta-
analysis, at least two studies considered comparable disease
in surgical and nonsurgical groups [19, 22]; in the study
of Osborne et al. pre-treatment statuses between surgical
resection and embolization were similar, and in the study
of Ahmed et al. the di,erence is unlikely to be due only to
patient selection [21]. Even the analysis of the two studies
with comparable characteristics was in the same direction of
the global analysis, and thus in favour of hepatic resection
[19, 22]. Another weakness of our study is related to the
great heterogeneity andwide variety in conservative therapies
undertaken for NETs, which is due to the observational
nature of the included studies. To overcome this weakness we
subdivided the analysis considering separately the two studies
comparing only surgery and embolization. Also in these two
studies we found an advantage of surgical resection over
conservative treatment (only embolization in this subgroup)
in terms of overall survival. )is further analysis resulted in
the same direction as the overall analysis thus in favor of
surgical resection.)erefore, we found a signi*cant increased
survival in the surgical hepatic resection group, and this data
requires further evidence from randomized clinical trials in
order to obtain a de*nitive answer to a really important
question like the survival gain in these patients.
Our literature search results included only one study
about liver transplant and we could not do any meta-analysis
[24]. Recurrence a.er liver transplantation to treat NETs
remains a signi*cant concern, and considering the high
morbidity and mortality associated with this procedure the
indication of symptom relief alone must outweigh the sig-
ni*cant risks [53]. Appropriate selection criteria and further
international multicentric studies are needed to demonstrate
survival and clinical bene*ts of this procedure.
5. Conclusion
Liver metastases are frequently encountered in patients with
NETs; these secondaries have an important role in the
prognosis.)e published observational studies and our paper
were supporting the surgical solution for NET hepatic metas-
tases. But the observational and retrospective nature of these
studies was limiting the level of evidence to support this solu-
tion. Since no randomized trial has been published, which
could inform meaningfully about the sustained advantages
of hepatic resection, no certain conclusion on the impact of
this aggressive approach can be achieved. Our meta-analysis
based on observational studies found a signi*cant increased
survival a.er surgical hepatic resection, but randomized
clinical trials must be undertaken to achieve more evidence
about the role of surgical treatment in patients with liver
metastases from NETs.
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